-

06:18:34 PM

XGN Stock News

XGN - Exagen Inc

10/04/22 8:25 AM

Nasdaq : XGN

managementlow float

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company's rheumatoid arthritis

RHEA-AI

positive

09/20/22 4:05 PM

Nasdaq : XGN

low float

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022,

RHEA-AI

neutral

09/01/22 4:05 PM

Nasdaq : XGN

covid-19low float

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. I?aki Sanz at Emory University has led to a publication in Nature, found here. Exagen's clinical test offerings, run on

RHEA-AI

neutral

08/04/22 4:06 PM

Nasdaq : XGN

low float

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the

RHEA-AI

neutral

08/04/22 4:05 PM

Nasdaq : XGN

low float

Exagen Inc. Reports Second Quarter 2022 Results

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights:

RHEA-AI

neutral

07/25/22 4:05 PM

Nasdaq : XGN

conferenceslow float

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42 nd Annual Growth Conference, which takes place August 8-11, 2022, in Boston at the InterContinental Boston

RHEA-AI

neutral

07/21/22 4:05 PM

Nasdaq : XGN

earningslow float

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive

RHEA-AI

neutral

07/05/22 8:25 AM

Nasdaq : XGN

low float

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE(R) Lupus Delivers Unparalleled Utility

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE(R) testing enables decisive clinical action in the differential diagnosis for lupus. The Complement Activation

RHEA-AI

neutral

06/09/22 8:25 AM

Nasdaq : XGN

low float

Exagen Inc. Expands Coverage with MediNcrease

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC's national provider network, providing enhanced care to their approximately 7.5 million

RHEA-AI

positive

05/26/22 4:05 PM

Nasdaq : XGN

conferenceslow float

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42 nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chicago Hotel. Ron

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

XGN Data

IndustryDental Laboratories
Websitewww.exagen.com
CeoFortunato Rocca
Security nameExagen Inc
Issue typecs
SectorManufacturing
Sic code8071
Employees182
Tags
- Health Services
- Medical/Nursing Services
- Manufacturing
- Dental Laboratories
Address1261 Liberty Way Ste C
StateCalifornia
CityVista
Zip92081-8356
CountryUS
Phone18884521522

About Exagen Inc

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on the proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.